Hsbc Holdings PLC Acquires New Stake in Molina Healthcare, Inc $MOH

Hsbc Holdings PLC acquired a new stake in Molina Healthcare, Inc (NYSE:MOH) during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund acquired 138,117 shares of the company’s stock, valued at approximately $31,533,000. Hsbc Holdings PLC owned 0.26% of Molina Healthcare as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors also recently bought and sold shares of the company. Canada Pension Plan Investment Board acquired a new stake in shares of Molina Healthcare in the 2nd quarter worth $11,460,000. Castleark Management LLC acquired a new position in shares of Molina Healthcare during the second quarter worth about $7,728,000. Solas Capital Management LLC purchased a new position in Molina Healthcare during the second quarter worth about $9,198,000. Legal & General Group Plc purchased a new position in Molina Healthcare during the second quarter worth about $32,821,000. Finally, The Manufacturers Life Insurance Company acquired a new stake in Molina Healthcare in the second quarter valued at about $36,117,000. Hedge funds and other institutional investors own 98.50% of the company’s stock.

Analysts Set New Price Targets

A number of equities research analysts have weighed in on the company. Barclays lowered their price objective on Molina Healthcare from $184.00 to $180.00 and set an “underweight” rating on the stock in a report on Friday, July 24th. JPMorgan Chase & Co. increased their target price on Molina Healthcare from $169.00 to $191.00 and gave the stock a “neutral” rating in a research note on Monday, June 8th. Royal Bank Of Canada reduced their price target on Molina Healthcare from $248.00 to $218.00 and set a “sector perform” rating for the company in a report on Friday, July 24th. Robert W. Baird lifted their price target on Molina Healthcare from $124.00 to $163.00 and gave the company a “neutral” rating in a research note on Monday, May 11th. Finally, Mizuho set a $215.00 price objective on Molina Healthcare in a report on Monday, June 8th. Three equities research analysts have rated the stock with a Buy rating, twelve have assigned a Hold rating and two have assigned a Sell rating to the stock. According to data from MarketBeat, Molina Healthcare presently has a consensus rating of “Hold” and a consensus price target of $202.44.

Molina Healthcare Stock Down 1.7%

Shares of NYSE MOH opened at $198.97 on Friday. The stock has a market capitalization of $10.39 billion, a price-to-earnings ratio of -1,105.33, a price-to-earnings-growth ratio of 29.01 and a beta of 0.75. Molina Healthcare, Inc has a 52 week low of $121.06 and a 52 week high of $244.89. The firm has a 50-day moving average price of $211.41 and a 200 day moving average price of $179.49. The company has a quick ratio of 1.68, a current ratio of 1.68 and a debt-to-equity ratio of 0.95.

Molina Healthcare (NYSE:MOH) last issued its earnings results on Wednesday, July 22nd. The company reported $1.51 earnings per share for the quarter, topping the consensus estimate of $1.39 by $0.12. Molina Healthcare had a negative net margin of 0.02% and a positive return on equity of 3.73%. The company had revenue of $10.87 billion for the quarter, compared to analyst estimates of $10.83 billion. During the same period in the prior year, the business posted $5.48 earnings per share. The firm’s revenue for the quarter was down 4.8% compared to the same quarter last year. Equities research analysts anticipate that Molina Healthcare, Inc will post 5.29 EPS for the current fiscal year.

Molina Healthcare Profile

Molina Healthcare, Inc is a managed care company specializing in government-sponsored health insurance programs. The company offers Medicaid managed care plans, Medicare Advantage and prescription drug plans, and individual Marketplace plans under the Affordable Care Act. Through an integrated care model, Molina emphasizes preventive and primary care services, care coordination, and disease management to improve health outcomes for its members.

The company traces its roots to the early 1980s, when Dr.